Blockchain Registration Transaction Record

Annovis Bio Promotes Dr. Cheng Fang to Chief Scientific Officer

Annovis Bio (NYSE: ANVS) promotes Dr. Cheng Fang to chief scientific officer as it advances buntanetap toward Phase 3 Alzheimer's data and NDA submission.

This promotion signals Annovis Bio's strategic focus on advancing buntanetap through late-stage trials and toward regulatory approval. For investors and patients, it underscores the company's readiness to tackle key milestones in Alzheimer's and Parkinson's disease treatments, potentially bringing a novel therapy to market that targets multiple toxic proteins. The move also highlights the importance of strong scientific leadership in navigating the complex regulatory landscape for neurodegenerative disease drugs.